Irish differences from the UK position

Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that.

Documenting an access outcome, dated, because everything in this category expires.

As of June 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

Coming back to post #3, because the follow-up matters more than the original answer.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

post #4 is right about the mechanism and I think understates the practical bit.

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

post #8 answers the question as asked. The question underneath it is different.

Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.

On post #6 — agreed on the reasoning, with one qualification.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Coming back to post #9, because the follow-up matters more than the original answer.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

post #13 answers the question as asked. The question underneath it is different.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.